Literature DB >> 9286051

Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice.

K Hordnes1, T Tynning, T A Brown, B Haneberg, R Jonsson.   

Abstract

We have studied the cervicovaginal antibody responses in mice, by ELISA, following mucosal immunizations with group B streptococci (GBS) serotype III/R4. Immunizations were carried out either: (1) rectally with GBS alone; (2) rectally with GBS plus cholera toxin (CT); (3) nasally with GBS alone; (4) nasally with GBS+CT; or (5) nasally under general anesthesia with GBS+CT. Nasal immunizations with GBS alone led to at least tenfold higher levels of specific IgA-antibodies to GBS in cervicovaginal secretions than with any other immunization. These mucosal antibody levels were higher than after rectal immunizations, and 2-17 times higher than the corresponding IgA antibody levels in sera. Markedly lower cervicovaginal antibody levels were found in mice which had received GBS together with CT as a mucosal adjuvant than in mice immunized by the same routes with GBS alone. Our observations indicate that a nasal vaccine consisting of GBS might induce sufficient antibody levels to protect against genital colonization of these bacteria.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286051     DOI: 10.1016/s0264-410x(97)00021-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.

Authors:  H Bakke; K Lie; I L Haugen; G E Korsvold; E A Høiby; L M Naess; J Holst; I S Aaberge; F Oftung; B Haneberg
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.

Authors:  N Mielcarek; I Nordström; F D Menozzi; C Locht; J Holmgren
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection.

Authors:  B K Hvalbye; I S Aaberge; M Løvik; B Haneberg
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

4.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Authors:  B Haneberg; R Dalseg; E Wedege; E A Høiby; I L Haugen; F Oftung; S R Andersen; L M Naess; A Aase; T E Michaelsen; J Holst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

6.  Long-term immunological memory induced by recombinant oral Salmonella vaccine vectors.

Authors:  J J Kohler; L Pathangey; A Hasona; A Progulske-Fox; T A Brown
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

7.  Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.

Authors:  L M Hodge; M Marinaro; H P Jones; J R McGhee; H Kiyono; J W Simecka
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

9.  Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization.

Authors:  Jacqueline A Baker; Emma L Lewis; Leah M Byland; Maryam Bonakdar; Tara M Randis; Adam J Ratner
Journal:  Vaccine       Date:  2017-02-02       Impact factor: 3.641

10.  Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis.

Authors:  Saúl Rojas-Hernández; Marco A Rodríguez-Monroy; Rubén López-Revilla; Aldo A Reséndiz-Albor; Leticia Moreno-Fierros
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.